Your Hosts |
International Pharmaceutical Federation (FIP)
-------------------- |
Board of Pharmaceutical Sciences (BPS)
-------------------- |
Endorsing Organisation
|
|
Congress Secretariat |
International Pharmaceutical
Federation
FIP Congress & Conferences
P.O. Box 84200
NL-2508 AE The Hague
The Netherlands
Tel +31 70 3021982
Fax +31 70 3021998
Email congress@fip.org
Website www.fip.org
|
© FIP & EUFEPS,
2006-2007 |
|
|
|
Page Updated as of April 23,
2007 |
|
» Monday am
» Mondag pm
» Tuesday am
» Tuesday pm
» Wednesday am
» Wednesday pm
|
| |
Parallel
Symposium
Room: Auditorium
The era of personalised health
care: Impact on drug
discovery and development? |
Parallel
Symposium
Room: Forum
Is gene/protein delivery delivering? |
Parallel
Symposium
Room: N-O
Can ADME and PK be predicted from in silico/in vitro
data? |
|
Sponsoring Organisation
|
|
Sponsoring Organisation
|
|
| |
Co-chairs
M. E. Brewster, Beerse, Belgium
W. Sadee, Columbus, OH USA
Y. Sugiyama, Tokyo, Japan |
Co-chairs
H. Harashima, Sapporo, Japan
W. Hennink, Utrecht, The Netherlands |
Co-chairs
S. Pang, Toronto, Canada
H. van de Waaterbeemd, Alderly Park, United Kingdom |
| 08:30 |
Evaluating molecular genetic
factors in drug response: Search for drug targets and biomarkers
W. Sadee, Columbus, OH USA |
A multi-functional envelope
type nano device as a non-viral gene delivery system
H. Harashima, Sapporo, Japan |
Translation of in vitro data to the whole
organ
S. Pang, Toronto, Canada |
| 09:05 |
Predicting drug disposition
and response in individual patients: Role of drug transporters
for influx and efflux processes
Y. Sugiyama, Tokyo, Japan |
Cellular mechanisms of non-viral
DNA delivery
A. Urtti, Helsinki, Finland |
In vitro – in vivo extrapolation:
Best use of known-knowns to discover unknown-unknowns
A. Rostami-Hodjegan, Sheffield, United Kingdom |
| 09:40 |
Coffee
Break |
|
|
| 10:10 |
Biomarkers in drug development: How do they influence
clinical practice?
L.J. Lesko, Silver Spring, MD USA |
Intravenous siRNA for silencing target genes in
solid tomor
L. Huang, Chapel Hill, NC USA |
A computational systems biology approach to ADME/Tox
S. Ekins, New York, NY USA |
| 10:45 |
Pharmacogenomic analysis reveals determinants
of sensitivity and resistance to geldanamycin analogues: Role
of membrane transporters
Y. Huang, Pomona, USA
(MO-S01-1) |
Silencing of SOCS genes in cancer cells for effective
interferon cancer therapy: Enhancement of antitumor activity
of interferons by rnai-mediated silencing of socs gene expression
Y. Takahashi, Kyoto, Japan
(MO-S02-1) |
Assessment of computational and in vitro
methods as predictors of oral drug absorption
M. Yliperttula, Helsinki, Finland
(MO-S03-1) |
| 11:00 |
Pharmacogenetics: From research results to practical
guidelines
L. Grandia, The Hague, The Netherlands
(MO-S01-2) |
Gene expression and silencing for improved islet
transplantation
R. Mahato, Memphis, USA
(MO-S02-2) |
Volume of distribution predictions: understanding
the processes
T. Rodgers, Manchester, United Kingdom
(MO-S03-2) |
| 11:15 |
Posters
Lunch Break |
|
|
| |
Parallel
Symposium
Room: L
Metabolomics: What are the opportunities for biomarker discovery? |
Parallel
Symposium
Room: C-D
What benefits does Process Analytical Technology (PAT) bring
to the design and assurance of product quality? |
Parallel
Symposium
Room: A
What have we learnt from recent safety cases for new drug development?
ISPE Midyear Symposium
|
ISPE Midyear Symposium
 |
|
| |
Co-chairs
T. Hankemeier, Leiden, The Netherlands
I. Schuppe-Koistinen, Soedertaelje, Sweden |
Co-chairs
S. Folestad, Moelndal, Sweden
J. Pritchard, Loughborough, United Kingdom |
Co-chairs
H. Leufkens, Utrecht, The Netherlands
M. Sturkenboom, Rotterdam, The Netherlands |
| 08:30 |
Systems biology & metabolomics: How far are
we?
T. Hankemeier, Leiden, The Netherlands |
Real-time prediction and control of quality –
the mechanistic approach to PAT
S. Folestad, Moelndal, Sweden |
A pharmaco-epidemiological reflection
on recent drug safety cases
A. Walker, Boston, MA USA |
| 09:05 |
The application of metabolic profiling technologies
in biomarker discovery during drug R&D
I. Schuppe-Koistinen, Soedertaelje, Sweden |
The benefits of PAT in ICH and Japanese regulation
Y. Hiyama, Tokyo, Japan |
Class effects in drug safety
and management
H. Leufkens, Utrecht, The Netherlands |
| 09:40 |
Coffee
Break |
|
|
| 10:10 |
Metabolomics by CE-MS for biomarker discovery
T. Soga, Tsuruoka, Japan |
Academic progress and new initiatives
P. York, Bradford, United Kingdom |
Industry responding to learning
from safety cases
S. Perez-Gutthann, Barcelona, Spain |
| 10:45 |
A novel immunoassay for monitoring caffeine as
an environmental marker for pharmaceuticals input
J. J. Carvalho, Berlin, Germany
(MO-S04-1) |
Evaluation of in-line near infrared spectroscopy
for predicting tablet content uniformity during powder mixing
H. M. J. Salokangas, Espoo, Finland
(MO-S05-1) |
Influence of COX-inhibitors
on blood-brain barrier properties
B. Germann, Vienna, Austria
(MO-S06-1) |
| 11:00 |
Metabolomic approach for QA/QC on TCM material
medica processing procedures-using citrus reticulata as the
sample
W.-T. Chang, Taichung, China Taiwan
(MO-S04-2) |
Raman spectroscopy as a PAT in tablet manufacturing
A. Sakr, Cincinnati, USA
(MO-S05-2) |
Monitoring on drug-induced hepatopathy
and granulocytopenia using hospital database resources: Prescription
and laboratory data linkage
J. Kawakami, Hamamatsu, Japan
(MO-S06-2) |
| 11:15 |
Posters
Lunch Break |
|
|
|
Keynote
Presentation
Room: Auditorium |
Keynote
Presentation
Room: Forum |
|
| |
Chair
H. Leufkens, Utrecht, The Netherlands |
Chair
M. Hashida, Kyoto, Japan |
|
| 12:15 |
What are the main challenges for world health?
What should be done now and in the future?
R. Laing, Geneva, Switzerland
(KLM-1) |
Transforming ‘art’ into ‘science’
in dosage form design – achievements and challenges
P. York, Bradford, United Kingdom (KLM-2) |
| |
Round
Table Discussion
Room: L |
Round
Table Discussion
Room: A |
Round
Table Discussion
Room: C-D |
| 13:10 |
Science or business as the driver of new drug
development?
Convenor L.Z. Benet, San Francisco, CA USA |
Does regulation help to ’innovate’
or ’stagnate’ drug development?
Convenor L.J. Lesko, Silver Spring, MD USA |
How can the bioavailability of poorly absorbed
compounds be enhanced?
Convenor C.-M. Lehr, Saarbrücken, Germany |
| |
Parallel
Symposium
Room: Auditorium
Pharmacogenetics at the bedside? |
Parallel
Symposium
Room: N-O
What will be the impact of cell-based therapy? |
Parallel
Symposium
Room: Forum
Simulation and modelling in drug development
improves decisions, saving time and money?
|
| Sponsoring Organisation
 |
|
| |
Co-chairs
G.T. Tucker, Sheffield, United Kingdom
M. Schwab, Stuttgart, Germany |
Co-chairs
E. Cattaneo, Milan, Italy
S. Nakagawa, Osaka, Japan |
Co-chairs
D. Stanski, Basel, Switzerland/East Hanover, NJ USA
M. Danhof, Leiden, The Netherlands |
| 14:15 |
Pharmacogenetics – how far is reality from
expectation?
G.T. Tucker, Sheffield, United Kingdom |
Innovative neurogenic neural stem cell lines for
neurodegenerative disease
E. Cattaneo, Milan, Italy |
Applying mechanistic pharmacokinetic-pharmacodymanic
(PK/PD) models to drug development
M. Danhof, Leiden, The Netherlands |
| 14:50 |
Multiple gene pharmacogenetics in individualized
drug therapy
I. Ieri, Yonago, Japan |
Cancer immunotherapy using gentically modified
denritic cells
S. Nakagawa, Osaka, Japan |
Examples of modelling and simulation
in the pharmaceutical industry
C. Pillai, Basel, Switzerland |
| 15:25 |
Pharmacogenetics in cancer therapy
M. Schwab, Stuttgart, Germany |
Cardiac regeneration: Repopulating the heart
L.J. Field, Indianapolis, IN USA |
The role of innovative model-based
trial design to improve drug development
S. Duffull, Dunedin, New Zealand |
| 16:00 |
Pharmacogenetics in paediatric drug development
and utilisation: Are we going in the right direction?
E. H. J. Krekels, Leiden, The Netherlands
(MO-S07-1) |
A study of cell cycle and stem cell markers to
identify the factors responsible for cardiac regeneration in
mrl mice
F. Moseley, Reading, United Kingdom
(MO-S08-1) |
Using pharmacokinetic-pharmacodynamic
analysis in drug discovery. An example on the integration of
mechanistic, principle and conceptual effect markers.
S. Visser, Seodertaelje, Sweden
(MO-S09-1) |
| 16:15 |
The association of warfarin dosage in clinical
use and pharmacogenomics
Y.-H. Chen, Taipei, China Taiwan
(MO-S07-2) |
Alteration of endothelial cell function under
high-glucose condition: Association with both disruption of
cell-to-cell connection and non-muscle contraction
K. Nobe, Tokyo, Japan
(MO-S08-2) |
Quantification of alpha 1-adrenoceptor
concentration, ligand binding kinetics and inotropic response
in the perfused rat heart: a PK/PD modeling analysis
P. Sermsappasuk, Halle (Saale), Germany
(MO-S09-2) |
| |
EUFEPS
Afternoon Sessions |
Sponsoring Organisation
 |
|
Room: O
Strategic, innovative and critical drug research initiatives:
One year late
Chair
O.J. Bjerrum, Copenhagen DK |
Room: L
Pharmaceutical sciences research training and education: Needs
and supply
Chair
M. Van der Waart, Oss NL
|
Room: N-O
The EU Microdosing AMS Partnership Programme (EUMAPP)
Chair
R.A. de Zeeuw, Assen NL |
| 16:45-18:15 |
Strategic drug research initiatives in Europe:
Current and future needs
O.J. Bjerrum, Copenhagen DK
The European Innovative Medicines Technology Platform: Current
status 2007
B. Rainer, Brusels BE
Precompetitive industry collaboration in Europe: 18 months
experience of the InnoMed project on predictive toxicology
D. Tweats, Swansea UK
Precompetitive industry collaboration in Europe: 18 months
experience of the InnoMed project on biomarkers for Alzheimer’s
disease
P. Francis, London UK
Discussion
|
University perspective
S. de Smedt, Ghent BE
Industry perspective
J. Dirach, Copenhagen DK
PPP Reserach Perspective
V. Nickolson, Leiden NL
Discussion
|
Microdosing: Pros and cons in translational
medicine
C. Garner, York UK
EUMAPP: Objectives, approaches and current status
B. Oosterhuis, Zuidlaren NL
Microdosing: Servier strategy and expectations from EUMAPP
E. Foos-Gilbert, Courbevoie FR
Discussion
|
| |
|
|
|
| 13:10 |
|
|
|
| |
Parallel
Symposium
Room: L
Dirty vs selective drugs in the CNS?
|
Parallel
Symposium
Room: C-D
How will developments in chemical methods sustain pharmaceutical
industrial development? |
Parallel
Symposium
Room: A
How effective is the
globalisation/harmonisation of
pharmacovigilance? |
| Sponsoring Organisation
|
|
Endorsing Organisation
|
|
| |
Co-chairs
H. Meltzer, Nashville, TN USA
C. Sennef, Weesp, The Netherlands |
Co-chairs
T. Ohwada, Tokyo, Japan
U. Holzgrabe, Wuerzburg, Germany |
Co-chairs
F. Lekkerkerker, The Hague, The Netherlands
M. Braun, Rockville, MD USA |
| 14:15 |
Rational polypharmacy within
a single molecule: The basis for current antipsychotic treatment
H. Meltzer, Nashville, TN USA |
Process chemistry as leverage for drug development
and profitability in the pharmaceutical industry
T. Konoike, Amagasaki, Japan |
The science underlying the practice
of pharmacovigilance
N. Moore, Bordeaux, France |
| 14:50 |
The treatment of major depression:
Single or multiple target?
F. Artigas, Barcelona, Spain |
Active targeting of anticancer agents: Chemical
aspects of folate-drug conjugate design
I. Vlahov, West Lafayette, IN USA |
International variety in interpretation
and management of drug safety
N. Wathion, London, United Kingdom |
| 15:25 |
Muscarinic receptors as a target
in the treatment of disorders of the CNS: Antagonism, agonism
or both?
B. Dean, Melbourne, Australia |
The synthetic development of the anti-influenza
neuraminidase inhibitor oseltamivir phosphate (Tamiflu®):
A challenge for synthesis and process research
M. Karpf, Basel, Switzerland |
ICH, CIOMS, ISOP, ISPE and other
acronymic vehicles to enable harmonisation of pharmacovigilance
C-K. Shim, Seoul, South Korea |
| 16:00 |
Learning and memory impairments
in congenic C57BL/6NTac mice that lack the m2 muscarinic acetylcholine
receptor subtype
C. Wrenn, Des Moines, USA
(MO-S10-1) |
Random chemistry as a new tool for the generation
of small-compound libraries
U. Holzgrabe, Wuerzburg, Germany (MO-S11-1) |
Round
Table Discussion |
| 16:15 |
Neuronal protective effect of
recombinant arginine deiminase in a nitric oxide overexpression
cell culture system
H.-H. Yu, Taipei, China Taiwan
(MO-S10-2) |
Generation and application of 0-benzoquinone methides
bearing various substituents on the benzene ring
T. Ohwada, Tokyo, Japan
(MO-S11-2) |
Proactive risk management (plans):
Where are we?
Convenor F. Lekkerkerker, The Hague, The Netherlands |
| |
EUFEPS
Afternoon Sessions |
This Symposium is
a special one, organised on the occasion of the retirement
of Dr F. Lekkerkerker, Chair of the Dutch Medicines
Evaluation Board (MEB), which is supporting it. It will be followed
by a Reception for guests invited by the MEB. |
| |
Sponsoring Organisation
|
| |
Room: E
The European Pharma Sciences Leadership Forum (EuPSLF)
Chair
C.R. Noe, Vienna AT |
Room: C-D
Pharmaceutical sciences in silico learning systems: Value and
availability
Chair
N. Haider, Vienna AT |
| 16:45-18:15 |
Background, initiative and progress
H. H. Linden, Stockholm SE
Aims, ambitions and plans
R. Pellicciari, Perugia IT
Preparing for a changing world of science
C.R. Noe, Vienna AT
Discussion
|
Computer applications in pharmaceutical education
and research
S. Moss, Bath UK
Pharmasquare – Blended Learning in Pharmaceutical
Sciences
A. Vögtli, Basel CH
PharmXplorer, an integrated platform for e-learning in pharmaceutical
sciences
T. Langer, Innsbruck AT
Discussion
Session Sponsor
|
| |
Parallel
Symposium
Room: Forum
Druggability: A concept that will fill the pipeline?
|
Parallel
Symposium
Room: Auditorium
Drug targeting: How successful are we? |
Parallel
Symposium
Room: N-O
What is the state-of-the-science in receptor site modelling? |
Sponsoring Organisation
|
|
| |
Co-chairs
D. Nicholson, Oss, The Netherlands |
Co-chairs
M. Hashida, Kyoto, Japan
R. Duncan, Cardiff, United Kingdom |
Co-chairs
S. Dahl, Tromsoe, Norway
M. Ishiguru, Osaka, Japan |
| 08:30 |
Druggability and the concept
of ADME space
D. Smith, Sandwich, United Kingdom |
Drug and gene delivery by combination of ultrasound
and bubble liposomes
K. Maruyama, Kanagawa, Japan |
Genomics to drug targets by molecular modelling
S. Dahl, Tromsoe, Norway |
| 09:05 |
Drugability and drug-likeness:
A medicinal chemist’s view
B. Testa, Lausanne, Switzerland |
Polymeric conjugates as anticancer nanomedicines:
Mechanism of action and drug combinations
R. Duncan, Cardiff, United Kingdom |
Functional structural models of G protein coupled
receptors
M. Ishiguru, Osaka, Japan |
| 09:40 |
Coffee
Break |
|
|
| 10:10 |
Concave druggability of protein
surfaces for accelerating in silico screening
H. Shirai, Tsukuba, Japan |
Targeting with molecularly decorated nanoparticles
N. Peppas, Austin, TX USA |
Structure-based virtual screening
J. Irwin, San Francisco, CA USA |
| 10:45 |
Predicting druggable proteins
from amino acid sequence by a machine learning approach
C.W. Yap, Singapore, Singapore
(TU-S01-1) |
Prevention of cytokines responses in cardiac allograft
rejection by systemic injection of nf-kappa B decoy/mannosylated
cationic liposome complexes
Y. Higuchi, Kyoto, Japan
(TU-S02-1) |
Identification of a conserved hydrophobic asparagine-cage
as a constraint for family a GPCR activation
A. Jongejan, Amsterdam, The Netherlands
(TU-S03-1) |
| 11:00 |
Medicinal chemistry of hERG
optimisations
E. Moir, Newhouse, United Kingdom
(TU-S01-2) |
Squalenoylated-gemcitabine nanomedicine exhibits
potential in cancer therapy at preclinic
H. R. Lakkireddy, Châtenay-Malabry, France
(TU-S02-2) |
Delineating a powerful virtual screening protocol
for G-protein coupled receptors: Application to selective kappa
opioid receptor agonist, salvinorin a
N. Singh, Mississippi, USA
(TU-S03-2) |
| 11:15 |
Posters
Lunch Break |
|
|
| |
Parallel
Symposium
Room: A
What’s new in methods of measuring human drug response? |
Parallel
Symposium
Room: C-D
In silico product development
from molecule to man: Dream or reality? |
Parallel
Symposium
Room: L
Nutraceuticals: Are new methods of
evaluating risk/benefit required? |
Sponsoring Organisation
 |
|
| |
Co-chairs
A. Cohen, Leiden, The Netherlands
P. Macheras, Athens, Greece |
Co-chairs
P. York, Bradford, United Kingdom
V. Venkatasubramanian, West Lafayette, IN USA |
Co-chairs
H. Ohama, Tokyo, Japan
R. Oledzka, Warsaw, Poland |
| 08:30 |
The data intensive
first administration to man study – functional outcome
replaces tolerability: The impact of new measurement techniques
A. Cohen, Leiden, The Netherlands |
Structure, thermodynamics and kinetics of pharmaceutical
systems from molecular simulation
J. Anwar, Bradford, United Kingdom |
Risk analysis and evaluation of scientific evidence
for nutraceuticals in Japan
H. Ohama, Tokyo, Japan |
| 09:05 |
Pathophysiological
concepts as a basis for the measurement of treatment response
in inflammatory and obstructive airway disease
H. Reddel, Camperdown, Australia |
Computer aided design and optimisation for pharmaceutical
formulations
K. Takayama, Tokyo, Japan |
Risk assessment and benefit evaluation for neutraceuticals
J. Hathcock, Washington, DC USA |
| 09:40 |
Coffee
Break |
|
|
| 10:10 |
PET imaging for
evaluation of drug effects in neuropsychiatric disease
E. Rabiner, Greenford, United Kingdom, and New York,
NY USA |
Cyberinfrastructure enabled pharmaceutical products
design and engeneering opportunities and challenges
V. Venkatasubramanian, West Lafayette, IN USA |
Benefits of antioxidants
H.K. Biesalski, Hohenheim, Germany |
| 10:45 |
Sensitivity of the
items of the Montgomery Asberg depression rating scale to treatment
response: Impact of different endpoints on clinical study design
for antidepressant drugs
G. Santen, Leiden, The Netherlands (TU-S04-1) |
Expert system software for solid dosage form formulation
design.
E. Krausbauer, Basel, Switzerland (TU-S05-1) |
Organic vs. conventional apple juices: polyphenol
profile, anti-oxidant capacity, anti-cancer activity, and inflammatory
bowel disease modulator activity
E. Mejia-Meza, Pullman, USA
(TU-S06-1) |
| 11:00 |
Application of computation
in translational research: A randomized trial of intravesical
mitomycin c for superficial bladder cancer with 10-year follow-up
J. Au, Columbus, OH USA
(TU-S04-2) |
Fundamental understanding through simulations?
S.-M. Siiriä, Helsinki, Finland
(TU-S05-2) |
Effects of essential fatty acids on expression
level and function of P-glycoprotein in inflammatory bowel diseases
A. Nomura, Tokyo, Japan
(TU-S06-2) |
| 11:15 |
Posters
Lunch Break |
|
|
| |
Keynote
Presentation
Room: Auditorium |
Keynote
Presentation
Room: Forum |
|
Sponsoring Organisation
|
|
Sponsoring Organisation
|
|
| |
Chair
W. Sadee, Columbus OH USA |
Chair
T. Dingermann, Franfurt, Germany |
|
| 12:15 |
Are we meeting the challenges of resistance to
anti-infective drugs and of newly emerging infectious diseases?
L. Schlesinger, Columbus OH USA
(KLT-1) |
Will novel approaches to the treatment of cardiovascular
disease prove highly effective?
J. Kastelein, Amsterdam, The Netherlands
(KLT-2) |
| 13:10 |
Round
Table Discussion
Room: A |
Round
Table Discussion
Room: L |
Round
Table Discussion
Room: C-D |
Sponsoring Organisation
|
|
| |
Translational science: a solution
to the productivity gap?
Convenor D. Nicholson, Oss, The Netherlands |
Can microdosing accelerate drug development?
Convenor A. Grahnen, Uppsala, Sweden |
When is a human bioequivalence study not needed?
Convenor L.Z. Benet, San Francisco, CA USA |
| |
Parallel
Symposium
Room: A
Drug-drug interactions: Avoid or understand? |
Parallel
Symposium
Room: N-O
What is the future of smart, feed-back, on-demand drug delivery
systems? |
Parallel
Symposium
Room: Forum
How are disease and PK-PD connected? |
| |
Co-chairs
K. Thummel, Seattle, WA USA
A. McLachlan, Sydney, Australia |
Co-chairs
J. Kopecek, Salt Lake City, USA
K. Kataoka, Tokyo, Japan |
Co-chairs
Y. Tanigawara, Tokyo, Japan
R. Bruno, Mountain View, CA USA |
| 14:15 |
Managing herb-drug interactions: Understanding
mechanism and educating the public
A. McLachlan, Sydney, Australia |
Smart drug delivery systems: State-of-the-art
and future directions
J. Kopecek, Salt Lake City, USA |
Bone disease progression and drug action
N. Holford, Auckland, New Zealand |
| 14:50 |
St John's wort - oxycodone interaction
D. Shen, Seattle WA USA |
Light-induced gene and drug delivery by supramolecular
nanocarrier
K. Kataoka, Tokyo, Japan |
Mechanism-based modelling of disease progression
– disease system analysis
B. Ploeger, Leiden, The Netherlands |
| 15:25 |
Application of a drug-drug interaction data base
in drug development and clinical education
K. Thummel, Seattle, WA USA |
Smart polymeric carriers for biomolecular drugs
P. Stayton, Seattle, WA USA |
Modelling of cancer progression and drug effects
R. Bruno, Mountain View, CA USA |
| 16:00 |
Sfinx – construction and implementation
of a novel drug drug interaction database
B. Eiermann, Stockholm, Sweden (TU-S07-1) |
Transdermal iontophoresis of dopamine agonist
5-OH-DPAT: Correlation of in vitro transport to the integrated
pk-pd profiles based on non-linear mixed effect modeling
A. K. Nugroho, Yogyakarta, Indonesia
(TU-S08-1) |
Pharmacokinetic-pharmacodynamic model for propofol
during long-term sedation in the critically ill patient
M. Peeters, Nieuwegein, The Netherlands
(TU-S09-1) |
| 16:15 |
Can we predict the magnitude of drug-drug interaction
in a simple way?: Simulation of interaction of rapidly-eliminating
drugs with fluvoxamine by dynamo-pk analysis method
K. Iga, Kyotanabe, Japan
(TU-S07-2) |
Biodegradable microparticles containing dexamethasone
and spions for intra-articular delivery
N. Butoescu, Geneva, Switzerland
(TU-S08-2) |
Population pharmacokinetic modelling of radioiodine
turnover in patients with Graves’ disease
I. Grabnar, Ljubljana, Slovenia
(TU-S09-2) |
| |
EUFEPS
Afternoon Sessions |
Sponsoring Organisation
|
| |
Room: E
European drug development centres and European growth areas
Chair
P. Vuorela, Turku FI |
Room: L
Reformulation of old drugs: Life cycle management
Chair
H. Blume, Oberursel DE |
Room: C-D
Vaccine delivery
Co-Chairs
J. Bouwstra, Leiden NL
W. Jiskoot, Leiden NL |
| 16:45-18:15 |
Center for New Drug Discovery Tools - DDTC
A. Urtti, Helsinki FI
The Pharma game, new rules, new players
V. Nickolson, Leiden NL
Drug development in the Medicon Valley: Importance of the
binational cluster and its international contacts
S. Gestrelius, Copenhagen DK
Discussion
|
Modified drug delivery – development
rationale for therapeutic improvement
E. Soederlind, Moelndal SE
Product preformance in the gastrointestinal tract and perspectives
for optimisation
W. Weitschies, Greifswald DE
Life Cycle Management: new chances for for old drugs
H. Blume, Oberursel DE
Discussion
Session Sponsor
|
Virosomes as a platform for improved influenza
vaccines
A. Huckriede, Groningen NL
Vaccines for Hepatitis B using DNA and sub-unit antigens
Y. Perrie, Aston UK
Challenges in non-invasive vaccine delivery
W. Jiskoot, Leiden NL
Discussion
|
| |
|
|
|
| 13:10 |
|
|
|
| |
Parallel
Symposium
Room: Auditorium
Have omics technologies improved the chance for successful drug
development? |
Parallel
Symposium
Room: L
Are pharmaceutical manufacturing technologies in stagnation? |
Parallel
Symposium
Room: C-D
Are we using the right outcome measures to ascertain patient
benefit from drug therapy? |
| |
Co-chairs
T. Guentert, Basel, Switzerland
M. Bleavins, Ann Arbor, MI USA |
Co-chairs
J. Fix, Lawrence, KS USA
Y. Capan, Ankara, Turkey |
Co-chairs
G. Skrepnek, Tucson, TX USA
A. Hussain, Dubai, United Arab Emirates |
| 14:15 |
Genomics and drug discovery: Have the promises been fulfilled?
K. Lindpaintner, Basel, Switzerland |
The changing landscape of pharmaceutical manufacturing: Incremental
or breaking new ground?
J. Fix, Lawrence, KS USA |
Outcomes measurement: Overview of theoretical and applied
issues
G. Skrepnek, Tucson, TX USA |
| 14:50 |
Omics and the search for improved
biomarkers
M. Bleavins, Ann Arbor, MI USA |
Innovation needed in pharmaceutical research and technology
in the 21st century
R. Ibuki, Yaizu, Japan |
Outcome measurement: Issues and strategies for pre-market
development
W-F Huang, Taipei, China Taiwan |
| 15:25 |
Changing the drug development paradigm: Opportunities offered
by new technologies
J. Kuromitsu, Tsukuba, Japan |
Can new production technologies and new excipients meet the
demands of future drugs?
H. Frijlink, Groningen,
The Netherlands |
Outcomes measurement: Issues and strategies for post-marketing
development
J. Cooke, Manchester, United Kingdom |
| 16:00 |
Microarray analysis of chlamydia pneumoniae infected human
epithelial cell line using gene ontology hierarchy
J.
Alvesalo, Helsinki, Finland
(TU-S10-1) |
Monitoring the modification of budesonide-lactose interactions
within dry powder inhaler formulations using atomic force microscopy
F. Buttini, Parma, Italy
(TU-S11-1) |
Abuse & misuse of lifestyle drugs in Korea
K. Kwon, Seoul, South-Korea
(TU-S12-1) |
| 16:15 |
Quantitative proteomic analysis of human renal cell carcinoma
using the NBS method
J. Matsumoto, Kobe, Japan
(TU-S10-2) |
Production of beclomethasone and salbutamol loaded poly(lactic
acid) nanoparticles by a novel electrospraying technique
L. Peltonen, Heksinki, Finland
(TU-S11-2) |
Combined prescriptions of cardiovascular drugs and Ginkgo
biloba in Taiwan: A population-based study
L.-C. Chang, Tapei, China Taiwan (TU-S12-2) |
| |
EUFEPS
Afternoon Sessions |
| |
Sponsoring Organisation
|
| |
Room: O
Pharmacogenetics & Pharmacogenomics Workshop: Outcomes and
plans
Chair
A-H. Maitland-van der Zee, Utrecht NL |
Room: A
How to start up a new company?
Co-Chairs
D. Crommelin, Leiden, The Netherlands
C. Bogentoft, Stockholm SE
|
Room: N-O
Drug product quality after new legislation
Chair
H. Köszegi-Szalai, Budapest HU |
| 16:45-18:15 |
Pharmacocgenetics of adverse drug reactions
M. Pirmohamed, Liverpool UK
Pharmacocgenetics in peadiatrics
E. Jacqz-Aigran, Paris FR
Methods in pharmacogenetics/genomics
A-H. Maitland-van der Zee, Utrecht NL
Discussion
|
Between chimney and ivory tower
D. Crommelin, Leiden, The Netherlands
The hands-on experience
G.T. Tucker, Sheffield UK
The Karolinska Innovation model in starting up companies
C. Bogentoft, Stockholm SE
Discussion
|
The impact of new guidance documents on the quality of
medicines in Europe
D. van Riet, Bilthoven NL
The present and the expectable future role of the EP in
the standardisation of the quality of medicines in Europe
H. Köszegi-Szalai, Budapest HU
Discussion
|
| |
Parallel
Symposium
Room: N-O
How to manage drug therapy at the extremes of age? |
Parallel
Symposium
Room: Forum
How can nanotechnology and materials science solve drug delivery
problems? |
Parallel
Symposium
Room: Auditorium
How important is genetic and physiological variability in drug
transporters? |
| |
Co-chairs
H. Derendorf, Gainesville, FL USA
H. Christensen, Oslo, Norway |
Co-chairs
C-M. Lehr, Saarbrucken, Germany
H. Ghandehari, Baltimore, USA |
Co-chairs
K. Giacomini, San Francisco, CA USA
K . Inui, Kyoto, Japan |
| 08:30 |
Pharmacotherapy in the elderly
H. Derendorf, Gainesville, FL USA |
Nanomedicines for overcoming biological barriers
C-M. Lehr, Saarbrucken, Germany |
Functional genomics of membrane transporters
K. Giacomini, San Francisco, CA USA |
| 09:05 |
Pharmacokinetics and pharmacodynamics in neonates
and infants
T. Dalla Costa, Porto Alegre, Brazil |
Particle design for absorption enhancement using
a 4-nozzle spray drier and DNA vaccine by self-organised Tat
nanospheres
H. Okada, Tokyo, Japan |
Pharmacogenomics of MDR1/ABCB1 and CYP3As in tacrolimus
therapy after organ transplantation
K . Inui, Kyoto, Japan |
| 09:40 |
Coffee
Break |
|
|
| 10:10 |
Dose optimisation in neonates, infants and children
S. Higuchi, Fukuoka, Japan |
Can higher definition of the nanoscale result
in better drug delivery systems in the 21st century?
H. Ghandehari, Baltimore, USA |
Assessing the impact of variability in ABC drug
transporters using mouse models
A. Schinkel, Amsterdam, The Netherlands |
| 10:45 |
Prediction of the oral bioavailability of midazolam
in the first 2 years of life
T. N. Johnson, Sheffield, United Kingdom
(WE-S01-1) |
Development of octaarginine-modified multifunctional
envelope-type nano device for gene delivery
K. Kogure, Sapporo, Japan
(WE-S02-1) |
Web-based comprehensive database for all about
drug transporters, “TP-Search”
K. Maeda, Tokyo, Japan
(WE-S03-1) |
| 11:00 |
Towards the in silico child: midazolam pharmacokinetics
using physiologically-based pharmacokinetic vs. non-linear mixed
effects modeling
S. Willmann, Leverkusen, Germany (WE-S01-2) |
In vitro studies into the biological fate of pva
nanoparticles for pulmonary delivery
M. Orlu, Istanbul, Turkey
(WE-S02-2) |
Regulatory mechanisms for gene expression of human
organic anion transporters
K. Ogasawara, Kyoto, Japan
(WE-S03-2) |
| 11:15 |
Posters
Lunch Break |
|
|
| |
Parallel
Symposium
Room: A
Systems biology: A driver of drug discovery and development? |
Parallel
Symposium
Room: C-D
How to engineer desired particle properties for drug delivery? |
Parallel
Symposium
Room: L
Off-label use of medicines: Abuse or a vehicle for innovation? |
| |
Sponsoring Organisation
|
|
Co-chairs
E. Fattal, Paris, France
T. Nagai, Tokyo, Japan |
Co-chairs
A. Kalis, The Hague, The Netherlands |
Co-chairs
C.R. Noe, Vienna, Austria |
| 08:30 |
Systems Biology: What does
it mean for pharmaceutical sciences?
A. Aszódi, Vienna, Austria
|
Particle design for nucleic acids and contrast
agents
E. Fattal, Châtenay-Malabry, France |
Two worlds and why the twain will never meet
J. Lisman, Amstedam, The Netherlands |
| 09:05 |
The theory of biological robustness
and its applications to medicine
H. Kitano, Tokyo, Japan |
Novel particle design for drug delivery
H. Takeuchi, Gifu, Japan |
Regulatory and ecomonic aspects of off-label drug
use
A. Wertheimer, Philadelphia, PA USA |
| 09:40 |
Coffee
Break |
|
|
| 10:10 |
Network-based drug design: target
identification by exploiting the system properties of metabolic
and gene-expression networks in parasites and their hosts
B. Bakker, Amsterdam, The Netherlands |
How to optimize particle properties for pulmonary
drug delivery
G. Hochhaus, Gainesville, FL USA |
The benefits of off-label grug use and its utilisation
K. Tsutani, Tokyo, Japan |
| 10:45 |
From enzymes to cells and back:
Integrating biochemical and cellular profiling of small molecule
kinase inhibitors
J. J. Hornberg, Oss, The Netherlands
(WE-S04-1) |
The role of particle characterization in the development
and dosage form evaluation of a poorly soluble pharmaceutical
drug product
R. Govoreanu, Beerse, Belgium
(WE-S05-1) |
On-label and off-label prescribing of erythropoietic
agents (epoetin alfa and darbepoetin alfa) in critically ill
patients: a multi-center, retrospective study
D. Holdford, Richmond, USA
(WE-S06-1) |
| 11:00 |
Pharmbiosim - biosimulation
of drug metabolism
J. Smolinski, Dresden, Germany
(WE-S04-2) |
Supercritical fluid particle design for increasing
dissolution rate of poorly-soluble active pharmaceutical ingredients
F. Deschamps, Champigneulles, France
(WE-S05-2) |
High rate of off-label use in cardiovascular paediatric
pharmacotherapy requires new focus in research
L. Hsien, Düsseldorf, Germany
(WE-S06-2) |
| 11:15 |
Posters
Lunch Break |
|
|
| |
Keynote
Presentation
Room: Auditorium |
Keynote
Presentation
Room: Forum
|
|
Sponsoring Organisation
 |
|
| |
Chair
J. Pritchard, Macclesfield, United Kingdom |
Chair
K. Midha, Saskatoon, Canada |
|
| 12:15 |
Drug resistance in cancer chemotherapy
T. Tsuruo, Tokyo, Japan
(KLW-1) |
Recent progress in prion biology
M. Heikenwaelder, Zurich, Switzerland
(KLW-2) |
| |
Round
Table Discussion
Room: A |
Round
Table Discussion
Room: L |
Round
Table Discussion
Room: C-D |
| 13:10 |
What is the value of observational data post-marketing
to assess safety and efficacy?
Convenor M. Rowland, Manchester, United Kingdom |
Life-style drugs: a new burden to the health system?
Convenor G. Alvan, Uppsala, Sweden |
Is there a consensus on guidelines for the evaluation
of biosimilars?
Convenor V. Shah, Rockville, MD USA |
| |
Parallel
Symposium
Room: N-O
Is the patient taking the tablets? |
Parallel
Symposium
Room: Auditorium
Developing biotech products: What are the challenges and solutions? |
Parallel
Symposium
Room: Forum
Control of intracellular pharmacokinetics: Advantages for drug
therapy? |
Sponsoring Organisation
|
|
| |
Co-chairs
M. Roberts, Brisbane, Australia
J. Kennedy, Cork, Ireland |
Co-chairs
M. Tsuchiya, Gotenba, Japan
S. Frokjaer, Copenhagen, Denmark |
Co-chairs
H. Kroemer, Greifswald, Germany
D. Roden, Memphis, TN USA |
| 14:15 |
When are dose administration aids of benefit?
M. Roberts, Brisbane, Australia |
The challenge of the next generation
of
therapeutic antibodies
M. Tsuchiya, Gotenba, Japan |
Transporter mediated cellular uptake of drugs
as a prerequisite for drug action
H. Kroemer, Greifswald, Germany |
| 14:50 |
Ambulatory patient’s variable adherence
with prescribed drug dosing regimens: Prevalence, patterns,
practicalities for drug trials and patient care
J. Urquhart, Palo Alto, CA USA, and Maastricht, The
Netherlands |
Drug delivery systems for biopharmaceuticals
S. Frokjaer, Copenhagen, Denmark |
Intracellular pharmacokinetics determines drug
action in patients with HIV
R. Kim, London, Canada |
| 15:25 |
Medication errors and human factors in medication
use safety
P. Schneider, Columbus, OH USA |
Efficient transepithelial delivery
of biopharmaceuticals
J. Mrsny, Cardiff, United Kingdom, and Menlo Park,
CA USA |
Understanding drug-induced arrhythmias –
from intracellular concentrations to candidate genes
D. Roden, Nashville, TN USA |
| 16:00 |
Routine use of dose administration aids (DAAs)
in the community - characteristics of Australian consumers making
this choice
J. Stokes, Brisbane, Australia
(WE-S07-1) |
Oral delivery of insulin by
new polysaccharide nanoparticles
B. Sarmento, Porto, Portugal
(WE-S08-1) |
Methods in drug discovery: measurement of unbound
intracellular drug concentrations
M. Friden, Uppsala, Sweden
(WE-S09-1) |
| 16:15 |
A cross-national study of persistence of antihypertensive
medication use in the elderly
B. L. Van Wijk, Utrecht, The Netherlands
(WE-S07-2) |
High pressure treatment for
the recovery of active protein from protein aggregates: An enabling
technology in comparison to traditional chaotrope-based refolding
methods
M. Seefeldt, Boulder, USA
(WE-S08-2) |
Uptake mechanisms of anti-hiv drugs, 2’,
3’-dideoxyinosine and 3’-azido-3’-deoxythimidine
by a conditionally immortalized syncytiotrophoblast cell line,
TR-TBT
K. Sato, Tokyo, Japan
(WE-S09-2) |
|
|
|
|
| 13:10 |
|
|
|
| |
Parallel
Symposium
Room: A
Molecular targeting in cancer chemotherapy? |
Parallel
Symposium
Room: C-D
Miniaturisation in analytical methods: Is small always beautiful? |
Parallel
Symposium
Room: L
Counterfeiting of medicines: Detection and prevention? |
| |
Co-chairs
J. Au, Columbus, OH USA
S. Eck, Ann Arbor, MI USA |
Co-chairs
S. Lunte, Lawrence, KS USA
J. Haginaka, Nishinomiya, Japan |
Co-chairs
A. Moffat, London, United Kingdom
Z. Y. Yang, Guangzhou, China |
| 14:15 |
The challenges of developing targeted cancer therapies: An
industry perspective
S. Eck, Ann Arbor, MI USA |
Separation based sensors for pharmaceutical analysis using
microdialysis and microchip electrophoresis
S. Lunte, Lawrence, KS USA |
New methods for detection of counterfeit medicines for laboratory
and field use
A. Moffat, London, United Kingdom |
| 14:50 |
A systems pharmacology: Targeting p53 networks
E. Liu, Singapore, Singapore |
Micro and nano chemical systems on chips for analytical and
biological sciences
T. Kitamori, Tokyo, Japan |
Analytical methods to detct and fingerprint counterfeit medicines
F. Fricke, Cincinnati, USA |
| 15:25 |
Translational research on a drug with multiple molecular targets
(suramin)
J. Au, Columbus, OH USA |
Microchip array strategies for biomarker detection using fluorescence
and MALDI TOF MS readout
T. Laurell, Lund, Sweden |
Combating counterfeit drugs in Asia
Z. Y. Yang, Guangzhou, China |
| 16:00 |
Anti-angiogenic actions of liposomal glucocorticoids on tumor
growth
M. Banciu, Utrecht, The Netherlands
(WE-S10-1) |
Molecular imaging of redox reaction using OMRI/nitroxyl probe
technique
K.-I. Yamada, Fukuoka, Japan
(WE-S11-1) |
Transfer of an NIR method for the authentication of tablets
and the detection of counterfeit versions
A. J. O’Neil, London, United Kingdom
(WE-S12-1) |
| 16:15 |
Characterization of paclitaxel-loaded immunonanoparticles
A. Cirstoiu-Hapca, Geneva, Switzerland
(WE-S10-2) |
|
Spurious drugs –epidemic threat to public health and
pharma industries
V. Mshra, Sagar, India
(WE-S12-2) |
|
|
